Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Calix, Raises Price Target to $70

Needham Maintains Buy on Calix, Raises Price Target to $70

Needham analyst Ryan Koontz maintains Calix (NYSE:CALX) with a Buy and raises the price target from $63 to $70.

byBenzinga Newsdesk

October 18, 2022

1 minute read

Needham analyst Ryan Koontz maintains Calix (NYSE:CALX) with a Buy and raises the price target from $63 to $70.

Analyst Ratings

The Latest Analyst Ratings for Newell Brands

By Benzinga Insights

July 20, 3:00 PM

Over the past 3 months, 9 analysts have published their opinion on Newell Brands (NASDAQ:NWL) stock. These analysts…

NWL

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Weibo

By Benzinga Insights

May 17, 2:01 PM

Ratings for Weibo (NASDAQ:WB) were provided by 4 analysts in the past three months, showcasing a mix of…

Oracle’s Larry Ellison And Microsoft’s Satya Nadella Bridge Decades-Long Rivalry

By Ananya Gairola

September 15, 4:37 AM

Larry Ellison, the founder of Oracle, and Satya Nadella, CEO of Microsoft, have announced a groundbreaking collaboration where Oracle's Exadata hardware will be integrated into Microsoft's Azure data centers.

MSFT

Data Published in “The Red Journal” Validate Clinical Utility Of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men With Intermediate-Risk Prostate Cancer

By Happy Mohamed

May 2, 4:38 PM

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial Veracyte, Inc. (NASDAQ:VCYT) announced that data published in

VCYT

Needham Maintains Buy on Calix, Raises Price Target to $70

Related Posts

The Latest Analyst Ratings for Newell Brands

Forecasting The Future: 4 Analyst Projections For Weibo

Oracle’s Larry Ellison And Microsoft’s Satya Nadella Bridge Decades-Long Rivalry

Data Published in “The Red Journal” Validate Clinical Utility Of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men With Intermediate-Risk Prostate Cancer